Zurich Cantonal Bank
RXRX icon

Zurich Cantonal Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Zurich Cantonal Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-159,548
Closed -$653K – 3346
2025
Q4 		$653K Buy
+159,548
New +$790K ﹤0.01% 1612

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Zurich Cantonal Bank's RXRX Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 214,851 shares worth $660K. The stake represents ﹤0.01% of the portfolio and ranks #1673 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in RXRX as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in RXRX in Q3 2021 and has held it in 17 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Zurich Cantonal Bank held 214,851 shares of Recursion Pharmaceuticals worth $660K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1673 holding.
  • Zurich Cantonal Bank first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.